MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 409.66K.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 409.66K.
Sobreavaliada
O PE mais recente da empresa é -5.95, em uma faixa percentil alta de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 6.15M ações, um aumento de 10.05% em relação ao trimestre anterior.
Mantido por James Simons
O Super Investidor James Simons possui 0.00 ações desta empresa.